|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.314 SEK | +5.80% |
|
+7.88% | -33.30% |
| 01/07 | IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors | CI |
| 30/06 | IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln | RE |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 111.6 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | -33.3% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 111.6 | 111.6 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | -33.3% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 1.09x | 0.79x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.09x | 0.79x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -4.04x | 2.99x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -3.53x | 3.35x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 102 | 141.8 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -27.6 | 37.3 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.6 | 33.3 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -32.6 | 33.3 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.314 | 1.314 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 84,938 | - |
| Announcement Date | 23/02/22 | 23/02/23 | 07/02/24 | 12/02/25 | 25/02/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.09Cr | |
| 34.84x | 12.66x | 25.79x | 0.57% | 1,06300Cr | |
| 27.14x | 6.24x | 16.98x | 2.1% | 61TCr | |
| 30.97x | 7.43x | 15.19x | 2.76% | 44TCr | |
| 17.52x | 4.36x | 10.71x | 3.05% | 32TCr | |
| 22.92x | 4.81x | 13.47x | 1.81% | 29TCr | |
| 21.57x | 5.54x | 13.39x | 2.85% | 28TCr | |
| 14.31x | 5.31x | 10.9x | 3.5% | 22TCr | |
| 23.55x | 6.27x | 11.03x | 2.79% | 20TCr | |
| -44.98x | 5.45x | 30.27x | 2.58% | 16TCr | |
| Average | 16.43x | 6.45x | 16.41x | 2.44% | 35.81TCr | |
| Weighted average by Cap. | 24.12x | 7.86x | 18.13x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
